Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G. Kvinnsland S, et al. Among authors: lobelle jp. Eur J Cancer. 2000 May;36(8):976-82. doi: 10.1016/s0959-8049(00)00041-1. Eur J Cancer. 2000. PMID: 10885600 Clinical Trial.
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Piccart MJ, et al. Among authors: lobelle jp. J Clin Oncol. 2001 Jun 15;19(12):3103-10. doi: 10.1200/JCO.2001.19.12.3103. J Clin Oncol. 2001. PMID: 11408507 Clinical Trial.
Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control.
Paridaens R, Dirix L, Beex L, Nooij M, Cufer T, Lohrisch C, Biganzoli L, Van Hoorebeeck I, Duchateau L, Lobelle JP, Piccart M. Paridaens R, et al. Among authors: lobelle jp. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S19-21. doi: 10.3816/cbc.2000.s.004. Clin Breast Cancer. 2000. PMID: 11970745 Clinical Trial.
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Paridaens R, et al. Among authors: lobelle jp. Ann Oncol. 2003 Sep;14(9):1391-8. doi: 10.1093/annonc/mdg362. Ann Oncol. 2003. PMID: 12954578 Free article. Clinical Trial.
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R. Atalay G, et al. Among authors: lobelle jp. Ann Oncol. 2004 Feb;15(2):211-7. doi: 10.1093/annonc/mdh064. Ann Oncol. 2004. PMID: 14760111 Free article. Clinical Trial.
44 results